Could this vaccine stop future coronavirus pandemics?

NCT ID NCT06950177

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Duke University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tests a new vaccine designed to protect against multiple coronaviruses, not just COVID-19. 51 healthy adults aged 18-55 will receive two doses to check safety and immune response. The vaccine uses a protein nanoparticle to target the virus's spike protein, aiming for broader protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CoV-RBD-scNP-001 vaccine with 3M-052-AF adjuvant
What this could lead to: If successful, this could lead to a vaccine that protects against many different coronaviruses, including future pandemic threats.
What could go wrong: This is a very early Phase 1 trial with only 51 healthy adults, so safety and immune response are still unknown. The vaccine may not work as hoped or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 RESPIRATORY INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 RESPIRATORY INFECTION COVID-19 VACCINE SARS-COV-2 INFECTION

Contacts and locations

Locations

Duke University Health System

Durham, North Carolina, 27709, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.